SCD and breast carcinoma: The insensitivity of breast cancer cells to atorvastatin treatment was determined to be due to increased unsaturated fatty acid metabolism and cholesterol biosynthesis through the induction of stearoyl-CoA desaturase (SCD) and 3-hydroxy03-methylglutaryl-CoA reductase (HMGCR), respectively [170].